Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Innovent Biologics

Biotech & Life Sciences · Suzhou Shi, China · Founded 2011 · IPO 2018 Decacorn

Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies

Valuation
$17B
Market cap · May/2026
Revenue
$1.79B
Latest reported FY
EBITDA
$344M
Latest reported FY

Investors

20 investors on Innovent Biologics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 19 investors entered at this stage
Apricot Capital
Temasek
Zhonghe Capital
Lilly Asia Ventures
Cormorant Asset Management
SDIC Fund Management
Ping An Capital
Frontline BioVentures
Capital Group
Hillhouse Capital
Taikang Life Insurance
Eight Roads Ventures
State Development & Investment Corporation (SDIC)
Rock Springs Capital
Legend Capital
China Life Private Equity Investment
Ping An Group
Ally Bridge Group
China Shenzhen New Venture Capital

Global footprint

Where Innovent Biologics has talent and traffic

Workforce by country
9 countries with
team presence
🇨🇳 China88.3%
🇺🇸 United States7.8%
🇭🇰 Hong Kong1.5%
🇸🇬 Singapore0.9%
🇬🇧 United Kingdom0.5%
Top 5 of 9 shown
Web traffic by country
21K monthly visits
across markets
🇺🇸 United States21%
🇨🇳 China16.7%
🇩🇰 Denmark16.2%
🇭🇰 Hong Kong15.7%
🏳️ Korea12.9%
Top 5 markets shown

Patent intelligence

$76M patent portfolio · 148 active families

Estimated portfolio value
$76M
0.46% of market cap · 26.5× smaller than top peer Ablynx ($2B)
148 active patent families
Where Innovent Biologics innovates Molecular biologyAntiendomysial antibodiesPharmaceutical drugImmunologyNucleic acid

Where Innovent Biologics concentrates vs peers

Each axis is a top-10 topic across Innovent Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Innovent Biologics's 2 investments and acquisitions.

Every disclosed deal where Innovent Biologics appeared as a backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Innovent Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Innovent Biologics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Innovent Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Innovent Biologics

        An AI-synthesized read of the highest-engagement posts about Innovent Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Innovent Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.